TriangleHEALTH PROFESSIONAL · SOURCE READING
Epcoritamab
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Epcoritamab is a bispecific T-cell engager that binds to CD20 and CD3.
Evidence (epcoritamab):
A single-arm multicenter study (NCT03625037), included 128 patients with relapsed or refractory follicular lymphoma who had received two or more lines of therapy. Patients received epcoritamab.[28]
Source links and citations
A single-arm multicenter study (NCT03625037), included 128 patients with relapsed or refractory follicular lymphoma who had received two or more lines of therapy. Patients received epcoritamab.[28]
With a median follow-up of 17.4 months, the overall response rate was 82.0 % (95% CI, 74.3%–88.3%) and the complete response rate was 62.5% (95% CI, 53.5%–70.9%).[28][Level of evidence C3]
Source links and citations
A single-arm multicenter study (NCT03625037), included 128 patients with relapsed or refractory follicular lymphoma who had received two or more lines of therapy. Patients received epcoritamab.[28]
Only 2% of patients had grade 3 or higher cytokine release syndrome events.
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice